Top 5 Stocks to Buy Now
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free AKTS Stock Alerts

Aktis Oncology (AKTS) Short Interest Ratio & Short Volume

Aktis Oncology logo
$24.09 +0.56 (+2.38%)
Closing price 04:00 PM Eastern
Extended Trading
$24.60 +0.51 (+2.10%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Aktis Oncology Short Interest Overview

As of May 29, 2026, Aktis Oncology (AKTS) had a short interest of 2.67 million shares sold short, representing 4.99% of the public float. This marks a 5.51% increase in short interest since the prior report. The short interest ratio (days to cover) is 18.4, meaning it would take 18.4 days of the average trading volume of 238,336 shares to cover all short positions.

Current Short Interest
2,666,881 shares
Previous Short Interest
2,527,598 shares
Change Vs. Previous Month
5.51%
Dollar Volume Sold Short
$55.31 million
Short Interest Ratio
18.4 Days to Cover
Last Record Date
May 29, 2026
Outstanding Shares
53,400,000 shares
Short Percent of Float
4.99%
Today's Trading Volume
552,135 shares
Average Trading Volume
238,336 shares
Today's Volume Vs. Average
232%
Short Selling Aktis Oncology?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Aktis Oncology and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

AKTS Short Interest Over Time

AKTS Days to Cover Over Time

AKTS Percentage of Float Shorted Over Time

Aktis Oncology Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/29/20262,666,881 shares $55.31 million +5.5%5.0%18.39 $20.74
5/15/20262,527,598 shares $49.41 million -1.7%4.9%16.71 $19.55
4/30/20262,570,690 shares $48.20 million +9.8%4.8%10.04 $18.75
4/15/20262,341,899 shares $42.36 million +0.9%4.5%8.36 $18.09
3/31/20262,320,091 shares $41.51 million +99.1%4.5%3.01 $17.89
2/27/20261,000,396 shares $20.14 million +8.8%1.9%5.96 $20.13
11/30/20247,250,000 shares $732.25 thousand +102.0%N/A0.3 $0.10
11/15/20243,590,000 shares $227.97 thousand -32.7%N/A0.2 $0.06
10/31/20245,330,000 shares $297.95 thousand +300.8%N/A0.4 $0.06
10/15/20241,330,000 shares $85.92 thousand -5.7%N/A0.1 $0.06
9/30/20241,410,000 shares $126.20 thousand -49.6%N/A0.2 $0.09
9/15/20242,800,000 shares $156.52 thousand -39.7%N/A0.3 $0.06
8/31/20244,640,000 shares $374.91 thousand -45.3%N/A0.6 $0.08
8/15/20248,480,000 shares $756.42 thousand +106.8%N/A0.9 $0.09
7/31/20244,100,000 shares $494.46 thousand -26.8%N/A0.3 $0.12
7/15/20245,600,000 shares $737.52 thousand -8.9%N/A0.4 $0.13
6/30/20246,150,000 shares $809.96 thousand -17.6%N/A0.4 $0.13
6/15/20247,460,000 shares $987.70 thousand -27.9%N/A0.6 $0.13
5/31/202410,340,000 shares $2.22 million +27.3%N/A0.9 $0.22
5/15/20248,120,000 shares $3.38 million -18.6%N/A0.8 $0.42
4/30/20249,970,000 shares $5.85 million +5.1%N/A14.9 $0.59
4/15/20249,490,000 shares $4.99 million +0.5%N/A11 $0.53
3/31/20249,440,000 shares $5.58 million +9.6%N/A10.4 $0.59
3/15/20248,610,000 shares $4.68 million +13.6%N/A9.1 $0.54
2/29/20247,580,000 shares $4.71 million -9.8%N/A8.2 $0.62
2/15/20248,400,000 shares $6.17 million +3.8%N/A9.1 $0.74
1/31/20248,090,000 shares $4.64 million +17.4%N/A9.5 $0.57
1/15/20246,890,000 shares $4.50 million -5.0%N/A10.2 $0.65
12/31/20237,250,000 shares $6.05 million -3.5%N/A11.3 $0.83
12/15/20237,510,000 shares $5.82 million -0.3%N/A11.6 $0.77
11/30/20237,530,000 shares $4.29 million +9.1%N/A10 $0.57
11/15/20236,900,000 shares $5.22 million -2.7%N/A7.3 $0.76
10/31/20237,090,000 shares $3.59 million +1.1%N/A7.6 $0.51
10/15/20237,010,000 shares $5.26 million +9.2%N/A7.5 $0.75
9/30/20236,420,000 shares $4.83 million -3.5%N/A6.5 $0.75
9/15/20236,650,000 shares $5.63 million -7.9%N/A6.9 $0.85
8/31/20237,220,000 shares $10.90 million +9.7%N/A8.5 $1.51
8/15/20236,580,000 shares $12.17 million +15.6%N/A12 $1.85
7/31/20235,690,000 shares $13.60 million +0.5%N/A10.2 $2.39
7/15/20235,660,000 shares $15.57 million +2.5%N/A10.3 $2.75
Do NOT buy or sell SPCX before reading this (Ad)

SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much as 7,100% - buying SPCX stock isn't the best way to profit. A hidden SpaceX division, already live across the American South and unrelated to its launch business, could be worth 100 times more than SpaceX's core operations. Rob Spivey, Director of Research at Altimetry, breaks down exactly what it is and how to position for it.tc pixel

See the better way to potentially profit from the SpaceX IPO
6/30/20235,520,000 shares $17.55 million +3.2%N/A11.1 $3.18
6/15/20235,350,000 shares $16.59 million -3.4%N/A10.5 $3.10
5/31/20235,540,000 shares $17.51 million -4.0%N/A9.8 $3.16
5/15/20235,770,000 shares $16.91 million +2.9%N/A9.7 $2.93
4/30/20235,610,000 shares $15.99 million +2.9%N/A8.6 $2.85
4/15/20235,450,000 shares $17.33 million -1.8%N/A6.9 $3.18
3/31/20235,550,000 shares $17.09 million +11.7%N/A6.9 $3.08
3/15/20234,970,000 shares $15.75 million +11.7%N/A6.2 $3.17
2/28/20234,450,000 shares $16.64 million +11.0%N/A6.4 $3.74
2/15/20234,010,000 shares $17.00 million -5.9%N/A6.1 $4.24
1/31/20234,260,000 shares $15.72 million -14.1%N/A6.7 $3.69
1/15/20234,960,000 shares $18.35 million +0.8%N/A9.7 $3.70
12/30/20224,920,000 shares $13.87 million +10.6%N/A11.5 $2.82
12/15/20224,450,000 shares $15.00 million -0.9%N/A10.6 $3.37
11/30/20224,490,000 shares $17.06 million -0.9%N/A10.4 $3.80
11/15/20224,530,000 shares $17.44 million -4.2%N/A10.3 $3.85
10/31/20224,730,000 shares $15.75 million -3.9%N/A11.1 $3.33
10/15/20224,920,000 shares $11.86 million -2.6%N/A12.2 $2.41
9/30/20225,050,000 shares $15.00 million -4.5%N/A15.2 $2.97
9/15/20225,290,000 shares $20.53 million +0.4%N/A16.8 $3.88
8/31/20225,270,000 shares $23.08 million +0.2%N/A15.6 $4.38
8/15/20225,260,000 shares $27.35 million -8.4%N/A14 $5.20
7/31/20225,740,000 shares $24.57 million -3.9%N/A13.3 $4.28
7/15/20225,970,000 shares $21.43 million +2.1%N/A11.6 $3.59
6/30/20225,850,000 shares $21.65 million -0.3%N/A11 $3.70
6/15/20225,870,000 shares $20.66 million +2.4%N/A10.4 $3.52
5/31/20225,730,000 shares $22.92 million +1.6%N/A10.8 $4.00
5/15/20225,640,000 shares $21.94 million -0.7%N/A10.6 $3.89
4/30/20225,680,000 shares $25.22 million +6.8%N/A10.1 $4.44
4/15/20225,320,000 shares $29.58 million -4.1%N/A9.1 $5.56
3/31/20225,550,000 shares $36.08 million -2.5%N/A9 $6.50
3/15/20225,690,000 shares $30.16 million -0.9%N/A9.2 $5.30
2/28/20225,740,000 shares $36.16 million -1.7%N/A8.4 $6.30
2/15/20225,840,000 shares $35.45 million +4.7%N/A8.2 $6.07
1/31/20225,580,000 shares $33.76 million +15.5%N/A8.3 $6.05
1/15/20224,830,000 shares $28.45 million +11.8%N/A7.8 $5.89
12/31/20214,320,000 shares $28.86 million +8.0%N/A7.2 $6.68
12/15/20214,000,000 shares $27.88 million +1.8%N/A6.7 $6.97
11/30/20213,930,000 shares $27.27 million -2.5%N/A7.6 $6.94
11/15/20214,030,000 shares $31.39 million -7.1%N/A7.6 $7.79
10/29/20214,340,000 shares $32.64 million +1.2%N/A8.7 $7.52
10/15/20214,290,000 shares $37.54 million -11.4%N/A9.3 $8.75
9/30/20214,840,000 shares $46.95 million -0.2%N/A11.3 $9.70
9/15/20214,850,000 shares $47.38 million +0.2%N/A11.5 $9.77
8/31/20214,840,000 shares $48.01 million -1.8%N/A10.5 $9.92
8/13/20214,930,000 shares $43.14 million -5.6%N/A11.3 $8.75
7/30/20215,220,000 shares $50.53 million +7.2%N/A11.3 $9.68
7/15/20214,870,000 shares $46.80 million -1.0%N/A9.2 $9.61
6/30/20214,920,000 shares $52.69 million +12.6%N/A9 $10.71

AKTS Short Interest - Frequently Asked Questions

Short interest is the volume of Aktis Oncology shares that have been sold short but have not yet been covered or closed out. As of May 29th, traders have sold 2,666,881 shares of AKTS short. 4.99% of Aktis Oncology's shares are currently sold short. Learn More on Aktis Oncology's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKTS shares currently have a short interest ratio of 18.4. Learn More on Aktis Oncology's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.99% of Aktis Oncology's floating shares are currently sold short.

Aktis Oncology saw a increase in short interest in May. As of May 29th, there was short interest totaling 2,666,881 shares, an increase of 5.5% from the previous total of 2,527,598 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

4.99% of Aktis Oncology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aktis Oncology: Erasca, Inc. (11.95%), Oruka Therapeutics, Inc. (13.81%), Catalyst Pharmaceuticals, Inc. (7.47%), Veradermics, Incorporated (5.66%), Kiniksa Pharmaceuticals International, plc (8.23%), Edgewise Therapeutics, Inc. (12.89%), ACADIA Pharmaceuticals Inc. (9.30%), NewAmsterdam Pharma Company N.V. (7.94%), Crinetics Pharmaceuticals, Inc. (12.46%), Organon & Co. (7.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($81.27 billion), Invesco QQQ ($49.06 billion), iShares Russell 2000 ETF ($23.61 billion), Western Digital Corporation ($16.93 billion), Sandisk Corporation ($15.61 billion), Salesforce Inc. ($11.65 billion), SPDR S&P Biotech ETF ($10.52 billion), Nebius Group N.V. ($10.24 billion), Lumentum Holdings Inc. ($8.74 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($8.21 billion). View all of the most shorted stocks.

Short selling AKTS is an investing strategy that aims to generate trading profit from Aktis Oncology as its price is falling. AKTS shares are trading up $0.56 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Aktis Oncology occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKTS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKTS, twice per month. The most recent reporting period available is May, 29 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like AKTS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:AKTS) was last updated on 6/18/2026 by MarketBeat.com Staff.
From Our Partners
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Hopeless About Retirement? Hopeless and Helpless Aren’t the Same Thing
Your retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...
Golden Portfolio | Sponsoredtc pixel
Do NOT buy or sell SPCX before reading this
SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Tesla's robot factory goes live this summer
On Tesla's Q1 2026 earnings call, Elon Musk confirmed Optimus robot production at the Fremont factory begins l...
StocksToTrade | Sponsoredtc pixel
A 3M Oz. Historical Gold Resource And A Market That Hasn't Caught Up
One Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...
Wall Street Logic | Sponsoredtc pixel